|
Bayer: continuing growth momentum
|
28 February 2013 |
|
Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of patients with gastrointestinal stromal tumors
|
25 February 2013 |
|
Bayer receives approval for new long-term contraceptive Skyla™ in the U.S.
|
09 January 2013 |
|
Bayer's "Perspective on Innovation 2012"
|
15 November 2012 |
|
The largest clinical study of Bayer's Xarelto® (rivaroxaban)
|
13 November 2012 |
|
Bayer on track for a successful 2012
|
30 October 2012 |
|
Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of metastatic colorectal cancer
|
30 September 2012 |
|
Bayer joins global initiative for better access to safe and effective contraception
|
26 September 2012 |
|
Bayer HealthCare starts special lab space-model CoLaborator™ for promising life science companies
|
11 September 2012 |
|
Bayer reports strong business performance in the second quarter of 2012
|
31 July 2012 |
|
FDA grants priority review to the new drug application for Bayer's Regorafenib
|
28 June 2012 |
|
Bayer's Regorafenib submitted for EU and US marketing authorization
|
23 May 2012 |
|
Encouraging start to the year for Bayer
|
26 April 2012 |
|
Bayer HealthCare and Beijing's Tsinghua University extend innovative drug discovery partnership
|
28 March 2012 |
|
Bayer HealthCare to Share Lab Space with Start-Up Companies
|
09 January 2012 |
|
Four potential blockbusters in the Pharma pipeline
|
20 December 2011 |
|
Bayer plans further expansion in Asia
|
16 November 2011 |
|
After a good third quarter: Bayer confirms Group outlook
|
28 October 2011 |
|
Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership
|
17 October 2011 |
|
Bayer Confident in Results of ROCKET AF Study
|
07 September 2011 |